Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Oncology Leader Liz Barrett Joins UroGen As CEO As It Heads Towards Commercial Stage

Executive Summary

The former Novartis Oncology CEO will oversee the FDA approval and launch of UroGen's lead asset, UGN-101, for low-grade upper tract urothelial cancer, and build out the company's longer-term strategy. Scrip talked to Barrett about the transition from big pharma leadership to the CEO of a small biopharma.

You may also be interested in...



UroGen Wins First FDA Approval With Jelmyto For Urothelial Cancer

Jelmyto relies on a proprietary sustained-release drug delivery technology that UroGen plans to use for future drugs. The company is moving ahead with a launch in June, relying on virtual technology. 

Urogen's Novel Formula For Urothelial Cancer Presents Unique Commercial Challenges

The company expects to launch a proprietary gel formulation of chemo drug mitomycin for urothelial cancer in the first half of 2020.

Finance Watch: Gossamer Works Around The Shutdown To Price Its $230m IPO

Gossamer took an infrequently used path to go public during a US government shutdown that's kept the SEC from processing new offerings. Also, IPO filings (and withdrawals) and follow-on offerings continued during the shutdown, while VC deals keep up a brisk pace.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC124424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel